DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Thursday, ValuEngine reports.
DBVT has been the subject of several other reports. Goldman Sachs Group started coverage on DBV TECHNOLOGIE/S in a research note on Monday, June 17th. They set a “buy” rating and a $14.00 target price for the company. BidaskClub upgraded DBV TECHNOLOGIE/S from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 6th. Finally, Zacks Investment Research upgraded DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Wednesday, July 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $14.81.
NASDAQ DBVT traded down $0.49 on Thursday, hitting $9.12. 134,482 shares of the company’s stock were exchanged, compared to its average volume of 277,552. The business has a 50-day moving average price of $9.34. The company has a current ratio of 3.34, a quick ratio of 3.30 and a debt-to-equity ratio of 0.01. DBV TECHNOLOGIE/S has a 52 week low of $3.60 and a 52 week high of $25.77. The company has a market cap of $571.19 million, a PE ratio of -2.69 and a beta of 1.81.
Several large investors have recently made changes to their positions in DBVT. Quantamental Technologies LLC increased its holdings in shares of DBV TECHNOLOGIE/S by 63.9% during the first quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock worth $38,000 after buying an additional 1,917 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of DBV TECHNOLOGIE/S during the second quarter worth $102,000. LeJeune Puetz Investment Counsel LLC acquired a new position in shares of DBV TECHNOLOGIE/S during the second quarter worth $108,000. Bank of Montreal Can acquired a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth $113,000. Finally, Aperio Group LLC acquired a new position in shares of DBV TECHNOLOGIE/S during the second quarter worth $152,000. Institutional investors own 46.47% of the company’s stock.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.